Download PDF
Hamostaseologie 1988; 08(01): 8-17
DOI: 10.1055/s-0038-1659943
Originalarbeiten
Schattauer GmbH

Vitamin K und medikamenteninduzierte Hypoprothrombinämie

H. Bechtold
*   Caritaskrankenhaus, Bad Mergentheim
,
K. Andrassy
**   Medizinische Universitäts-Klinik, Heidelberg
› Author Affiliations
Further Information

Publication History

Publication Date:
25 June 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Aus den vorliegenden Untersuchungen und aus den Mitteilungen der Literatur läßt sich auf die Bedeutung folgender zwei Faktoren für die Genese der Cephalosporin-induzierten HP schlieβen:

1. Latenter Vitamin-K-Mangelzustand des Organismus durch fehlende oder reduzierte exogene Vitamin-K-Zufuhr (z.B. bei ausschlieβlich parenteraler Ernährung) und möglicherweise durch Unterdrückung der Vitamin-K2-produzie-renden (Dünn-)Darmflora.

2. Kumarinartige Hemmung des Vit-amin-K1Stoffwechsels in der Leber durch bestimmte Cephalosporine (z.B. NMTT-Cephalosporine).

Das Zusammenwirken dieser Faktoren führt funktionell zu einem manifesten Vitamin-K-Mangelzustand, erkenntlich an einem Abfall der Vitamin-K-abhängigen Gerinnungsfaktoren. Aufgrund dieses Mechanismus ist es verständlich, daß die Cephalosporin-induzierte HP durch prophylaktische Vitamin-K1Gaben verhindert (ca. 10 mg Vitamin K1 pro Woche) bzw. eine manifeste HP korrigiert werden kann.

Der Vollständigkeit halber sei auf die hier nicht näher erläuterten Anta-bus®-ähnlichen Reaktionen nach Alkoholzufuhr hingewiesen, die - in Analogie zu der kumarinartigen Hemmung des Vitamin-K1Stoffwechsels -ebenfalls die Gruppe der NMTT- und MTD-Cephalosporine betreffen und durch entsprechende Alkoholkarenz vermeidbar sind (60).

 

  • Literatur

  • 1 Andrassy K, Bechtold H, Ritz E. Hypoprothrom-binemia caused by cephalosporins. J Antimicrob Chemother 1985; 15: 133-6.
    PubMedGoogle Scholar
  • 2 Ansell J.E, Kumar R, Deykin D. The spectrum of vitamin K deficiency. JAMA 1977; 238: 40-2.
    CrossrefPubMedGoogle Scholar
  • 3 Aronoff G.R, Wolen R.L, Obermeyer B.D, Black H.R. Pharmacokinetics and protein binding of cefamandole and its 1-methyl-1-H-tetrazole-5-thiol side chain in subjects with normal and impaired renal function. J Infect Dis 1986; 153: 1069-74.
    CrossrefPubMedGoogle Scholar
  • 4 Arvidsson A, Gunnar A, Angelin B, Borga O, Nord C.E. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother 1982; 10: 207-15.
    CrossrefPubMedGoogle Scholar
  • 5 Balant L, Dayer P, Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinet 1985; 10: 101-43.
    CrossrefPubMedGoogle Scholar
  • 6 Bang N.U, Tessler S.S, Heiderich R.O, Marks C.A, Mattler L.E. Effects of moxalactam on blood coagulation and platelet function. Rev Infect Dis 1982; 4 Suppl 546-54.
    CrossrefPubMedGoogle Scholar
  • 7 Bang N.U, Kammer R.B. Hematologic complications associated with β-lactam antibiotics. Rev Infect Dis 1983; 5 (Suppl. 02) 380-93.
    CrossrefPubMedGoogle Scholar
  • 8 Barckow D, Schirop T, Schwigon C.D. Blutgerinnungsstörungen bei Intensivpatienten unter Therapie mit Cephalosporinen. Intensivmed 1984; 21: 162-4.
    PubMedGoogle Scholar
  • 9 Barrow M.V, Quick D.T, Cunningham R.W. Salicylate hypothrombinemia in rheumatoid arthritis with liver disease. Arch Intern Med 1967; 120: 620-4.
    CrossrefPubMedGoogle Scholar
  • 10 Bechtold H. Untersuchungen zum Vitamin-K1 Stoffwechsel beim Menschen - Beziehung zur hypoprothrombinämischen Wirkung von Phen-procoumon, Acetylsalicylsäure und neueren Cephalosporinen. Habilitationsschrift, Universität Mainz 1985.
    PubMedGoogle Scholar
  • 11 Bechtold H, Andrassy K, Jähnchen E, Koderisch J, Koderisch H, Weilemann L, Sonntag H, Ritz E. Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. Thromb Haemost 1984; 51: 358-61.
    PubMedGoogle Scholar
  • 12 Bechtold H, Andrassy K, Koderisch J, Trenk D, Sonntag H, Jähnchen E. Coumarin-like inhibition of vitamin K metabolism by N-methyl-thiotetrazole cephalosporins - influence of the chemical structure of the side-chain. Haemosta-sis; Recent Advances and New Developments in Haemostaseology, 4th Congress of the Society on Thrombosis and Haemostasis, Düsseldorf 1986; A 157, p 117.
    PubMedGoogle Scholar
  • 13 Bechtold H, Andrassy K, Koderisch J, Trenk D, Sonntag H. Cumarinartige Hemmung des Vitamin-K1-Stoffwechsels durch strukturell unterschiedliche Cephalosporine. Fortschr antimikr antineoplast Chemother 1987; 6-4: 609-22.
    PubMedGoogle Scholar
  • 14 Bechtold H, Lorenz J, Weilemann L.S, Meinertz T, Trenk D, Andrassy K, Jähnchen E. Possible coumarin-like mechanism of action for cephalosporins. Klin Wschr 1984; 62: 885-6.
    CrossrefPubMedGoogle Scholar
  • 15 Bechtold H, Trenk D, Jähnchen E, Meinertz T. Plasma vitamin K1 2,3-epoxide as diagnostic aid to detect surreptitious ingestion of oral anticoagulant drugs. Lancet 1983; I: 595-7.
    PubMedGoogle Scholar
  • 16 Bechtold H, Trenk D, Meinertz T, Rowland M, Jähnchen E. Cyclic interconversion of vitamin K1 and vitamin K1-2,3-epoxide in man. Br J Clin Pharmacol 1983; 16: 683-9.
    CrossrefPubMedGoogle Scholar
  • 17 Bechtold H, Trenk D, Meinertz T, Jähnchen E. Effect of salicylate on the vitamin K1 metabolism in man. Naunyn-Schmiedebergs Arch Pharmacol 1984; 325 (Suppl): R12, A 48.
    PubMedGoogle Scholar
  • 18 Bell R.G. Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin epoxide cycle. Fed Proc 1978; 37: 2599-604.
    PubMedGoogle Scholar
  • 19 Bell R.G, Matschiner J.T. Warfarin and the inhibition of vitamin K activity by an oxide metabolite. Nature 1972; 237: 32-3.
    CrossrefPubMedGoogle Scholar
  • 20 Bjornssen T.D, Meffin R.J, Swezey S.E, Blaschke T.F. Effects of Clofibrate and warfarin alone and in combination on the disposition of vitamin K1 . J Pharmacol Exp Ther 1979; 210: 322-6.
    PubMedGoogle Scholar
  • 21 Black H.R, Buening M.K, Wolen R.L. Lata-moxef, its side chain, and coagulation. Lancet 1983; II: 1090.
    PubMedGoogle Scholar
  • 22 Bruch K. Hypoprothrombinaemia and cephalosporins. Lancet 1983; I: 535-6.
    PubMedGoogle Scholar
  • 23 Caldwell P.T, Ren P, Bell R.G. Warfarin and metabolism of vitamin K1 . Biochem Pharmacol 1974; 23: 3353-62.
    CrossrefPubMedGoogle Scholar
  • 24 Clouse L.H, Comp P.C. The regulation of hemostasis: the protein C system. N Engl J Med 1986; 314: 1298-304.
    CrossrefPubMedGoogle Scholar
  • 25 Conly J.M, Ramotar K, Chubb H, Bow E.Y, Louie T.J. Hypoprothrombinemia in febrile, neutropenic patients with cancer: association with antimicrobial suppression of intestinal microflora. J Infect Dis 1984; 150: 202-12.
    CrossrefPubMedGoogle Scholar
  • 26 Creedon K.A, McTigue J.J, Engelke J.A, Suttie J.W. Antibiotic induced hypoprothrombinemia: effect of NMTT on vitamin K-dependent reactions. Thromb Haemost 1985; 54: 150 (A 888)
    PubMedGoogle Scholar
  • 27 Creedon K.A, Suttie J.W. Effect of N-methyl-thiotetrazole on vitamin K in epoxide reductase. Thrombos Res 1986; 44: 147-53.
    CrossrefPubMedGoogle Scholar
  • 28 Dam H. The antihaemorrhagic vitamin of the chick. Biochem J 1935; 29: 1273-85.
    CrossrefPubMedGoogle Scholar
  • 29 Dam H, Søndegaard E, Olson R.E. Vitamin K. In: Barker B.M, Bender D.A. (eds) Vitamin in Medicine. 4th ed. London: Heinemann; 1982: 92-113.
    Google Scholar
  • 30 Frick P.G, Riedeler G, Brogli H. Dose response and minimal daily requirement for vitamin K in man. J Appl Physiol 1967; 23: 387-9.
    CrossrefPubMedGoogle Scholar
  • 31 Friedman P.A. Vitamin-K-dependent proteins. N Engl J Med 1984; 310: 1458-60.
    CrossrefPubMedGoogle Scholar
  • 32 Gallop P.M, Lian J.B, Hauschka P.V. Carboxyla-ted calcium-binding proteins and vitamin K. New Engl J Med 1980; 302: 1460-6.
    CrossrefPubMedGoogle Scholar
  • 33 Ganrot P.O, Niléhn J-E. Plasma prothrombin during treatment with dicumarol. II. Demonstration of an abnormal prothrombin fraction. Scand J Clin Lab Invest 1968; 22: 23-8.
    PubMedGoogle Scholar
  • 34 Graham G.G, Champion G.D, Day R.O.P, Pauli P.D. Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Clin Pharmacol Ther 1977; 22: 410-20.
    CrossrefPubMedGoogle Scholar
  • 35 Ham J. Hypoprothrombinemia in patients undergoing prolonged intensive care. Med J Austr 1971; 2: 716-9.
    PubMedGoogle Scholar
  • 36 Hauschka P.V. Osteocalcin in developing bone systems. In: Suttie J.W. Vitamin K Metabolism and Vitamin K-Dependent Proteins. Baltimore: University Park Press; 1979: 227-36.
    Google Scholar
  • 37 Hemker H.C, Veltkamp J.J, Hensen A, Loeliger E.A. Nature of prothrombin biosynthesis: pre-prothrombinaemia in vitamin K deficiency. Nature 1963; 200: 589-90.
    CrossrefPubMedGoogle Scholar
  • 38 Hildebrandt E.F, Suttie J.W. The effects of salicylate on enzymes of vitamin K metabolism. J Pharm Pharmacol 1983; 35: 421-6.
    CrossrefPubMedGoogle Scholar
  • 39 Hildebrand E, Suttie J.W. Indirect inhibition of vitamin K epoxide reduction by salicylate. J Pharm Pharmacol 1984; 36: 586-91.
    CrossrefPubMedGoogle Scholar
  • 40 Hochman R, Ciak J, Rolla A, Thomas S, Kaldany A, D’Elia J.A. Bleeding in patients with infections. Are antibiotics helping or hurting?. Arch Int Med 1982; 142: 1440-2.
    CrossrefPubMedGoogle Scholar
  • 41 Howard J.B, Nelsestuen G.L. Isolation and characterization of vitamin K-dependent region of bovine blood clotting factor X. Proc Natl Acad Sci USA 1975; 72: 1281-5.
    CrossrefPubMedGoogle Scholar
  • 42 Kager L, Malborg A.S, Nord C.E, Pieper R. The effect of short-term cefoxitin prophylaxis on the colonic microflora in patients undergoing colorectal surgery. Infection 1982; 10: 338-40.
    CrossrefPubMedGoogle Scholar
  • 43 Kerremans A.L, Lipsky J.J, van Loon J, Gallego M.O, Weishilboum R.M. Cephalosporin-induced hypoprothrombinemia: possible role for thiol methylation of 1-methyltetrazole-5-thiol and 2-methyl-1,2,4-thiadiazole-5-thiol. J Pharmacol Exp Ther 1985; 235: 382-8.
    PubMedGoogle Scholar
  • 44 Langenberg J.P. Bioanalysis of ultra-trace levels of K vitamins using electrofluorometric detection in HPLC. The influence of the variable vitamin K availability from normal diets on the stability of the oral anticoagulant therapy. Dissertation, Universität Leiden 1985.
    PubMedGoogle Scholar
  • 45 Langenberg J.P, Tjaden U.R. Determination of (endogenous) vitamin K1 in human plasma by reversed-phase high performance liquid chromatography using fluorometric detection after post-column electrochemical reduction. J Chromatogr 1984; 305: 61-72.
    CrossrefPubMedGoogle Scholar
  • 46 Larson A.E, Suttie J.W. Vitamin K-dependent carboxylase: evidence for a hydroperoxidase intermediate in the reaction. Proc Natl Acad Sci 1978; 75: 5413-6.
    CrossrefPubMedGoogle Scholar
  • 47 Link K.P. The discovery of dicoumarol and its sequels. Circulation 1959; 19: 97-107.
    CrossrefPubMedGoogle Scholar
  • 48 Lipsky J.J. N-methyl-thio-tetrazole inhibition of the gamma carboxylation of glutamic acid: possible mechanism for antibiotic associated hypoprothrombinemia. Lancet 1983; II: 192-3.
    PubMedGoogle Scholar
  • 49 Lipsky J.J. Mechanisms of the inhibition of the y-carboxylation of glutamic acid by N-methylthiote-trazole-containing antibiotics. Proc Natl Acad Sci 1984; 81: 2893-7.
    CrossrefPubMedGoogle Scholar
  • 50 Lipsky J.J, Lewis J.C, Novick W. Production of hypoprothrombinemia by moxalactam and 1-me-thyl-5-thiotetrazole in rats. J Antimicrob Chemother 1984; 25: 380-1.
    CrossrefPubMedGoogle Scholar
  • 51 Lipsky J.J, Lewis J.C, Novick Jr W.J. Production of hypoprothrombinemia by cefazolin and 2-methyl-1,3,4-thiadiazole-5-thiol in the rat. J Antimicrob Chemother 1986; 18: 131-7.
    PubMedGoogle Scholar
  • 52 Lowenthal J, MacFarlane J.A. The nature of the antagonism between vitamin K and indirect anticoagulants. J Pharmacol Exp Ther 1963; 143: 273-7.
    PubMedGoogle Scholar
  • 53 Magnusson S, Sottrup-Jensen L, Petersen T.E, Morris H.R, Dell A. Primary structure of the vitamin K-dependent part of prothrombin. FEBS Lett 1974; 44: 189-93.
    CrossrefPubMedGoogle Scholar
  • 54 Mandel H.G, Cohn V.H. Fat soluble vitamins. Vitamin A, K and E. In: Gilman A.G, Goodman L.S, Rail T.W, Murad F. (eds) The Pharmacological Basis of Therapeutics. New York: MacMillan; 1985: 1582-6.
    Google Scholar
  • 55 Matschiner J.T, Bell R.G, Amelotti J.M, Knauer T.E. Isolation and characterization of a new metabolite of phylloquinone in the rat. Biochim Biophys Acta 1970; 201: 309-15.
    CrossrefPubMedGoogle Scholar
  • 56 McCarthy P.T, Shearer M.J, Gau G, Crampton O.E, Barkhan P. Vitamin K content of human liver at different ages. In: Sutor A.H, Künzer W. (eds) Physiologie und Pathophysiologie des Vitamin K. Basel/Grenzach-Wyhlen: Editiones Roche; 1986: 95-104.
    Google Scholar
  • 57 Menge H. Sind Bakterien im Dünndarm pathogen und behandlungsbedürftig?. Leber Magen Darm 1986; 2: 82-92.
    PubMedGoogle Scholar
  • 58 Ñatelson E, Brown C, Bradshaw W, Alfrey C, Williams T. Influence of cephalosporin antibiotics on blood coagulation and platelet function. Antimicrob Agents Chemother 1976; 9: 91-3.
    CrossrefPubMedGoogle Scholar
  • 59 Nelsestuen G, Zytkovicz T.H, Howard J.B. The mode of action of vitamin K. Identification of γ-carboxyglutamin acid as a component of prothrombin. J Biol Chem 1974; 249: 6347-50.
    PubMedGoogle Scholar
  • 60 Neu H.C. Adverse effects of new cephalosporins. Ann Int Med 1983; 98: 415-6.
    PubMedGoogle Scholar
  • 61 Olson R.E. The function and metabolism of vitamin K. Ann Rev Nutr 1984; 4: 281-337.
    CrossrefPubMedGoogle Scholar
  • 62 O’Reilly R.A. Vitamin K and the oral anticoagulant drugs. Ann Rev Med 1976; 27: 245-61.
    CrossrefPubMedGoogle Scholar
  • 63 O’Reilly R.A. Anticoagulant, antithrombotic, and thrombolytic drugs. In: Gilman A.G, Goodman L.S, Rail T.W, Murad F. (eds) The Pharmacological Basis of Therapeutics. New York: MacMillan; 1985: 1338-59.
    Google Scholar
  • 64 Owens M.R, Cimino C.D. The interaction of salicylate and vitamin K in synthesis of factor II (prothrombin). Thromb Res 1983; 31: 135-43.
    CrossrefPubMedGoogle Scholar
  • 65 Pabinger-Fasching I. Protein C, ein in der Leber gebildeter Gerinnungsinhibitor. Hämostaseologie 1984; 2: 50-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Park B.K, Leck J.B. On the mechanisms of salicylate-induced hypoprothrombinemia. J Pharm Pharmacol 1981; 33: 25-8.
    CrossrefPubMedGoogle Scholar
  • 67 Park B.K, Wilson A.C, Kaatz G, Ohnhaus E.E. Enzyme induction by phenobarbitone and vitamin K, disposition in man. Br J Clin Pharmacol 1984; 18: 94-7.
    CrossrefPubMedGoogle Scholar
  • 68 Park B.K, Scott A.K, Wilson A.C, Haynes B.P, Beckenridge A.M. Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol 1984; 18: 655-62.
    CrossrefPubMedGoogle Scholar
  • 69 Pineo G.F, Gallus A.S, Hirsch J. Unexpected vitamin K deficiency in hospitalized patients. Can Med Assoc J 1973; 109: 880-3.
    PubMedGoogle Scholar
  • 70 Price P.A, Epstein D.J, Lothringer J.W, Nishimoto S.K, Poser J.W, Williamson M.K. Structure and function of the vitamin K-dependent protein of bone. In: Suttie J.W. Vitamin K Metabolism and Vitamin K-Dependent Proteins. Baltimore: University Park Press; 1979: 219-26.
    Google Scholar
  • 71 Romatar K, Conly J.M, Chubb H, Louie T.J. Production of menaquinones by intestinal anaerobes. J Infect Dis 1984; 150: 213-8.
    CrossrefPubMedGoogle Scholar
  • 72 Rothschild B.M. Hematologic perturbations associated with salicylate. Clin Pharmacol Ther 1979; 26: 145-52.
    CrossrefPubMedGoogle Scholar
  • 73 Sadowski J.A, Suttie J.W. Mechanism of action of coumarins. Significance of vitamin K epoxide. Biochemistry 1974; 13: 3696-9.
    CrossrefPubMedGoogle Scholar
  • 74 Sattler F.R, Weitekamp M.R, Bllard J.O. Potential bleeding with the new beta-lactam antibiotics. Ann Int Med 1986; 105: 924-31.
    CrossrefPubMedGoogle Scholar
  • 75 Shah D.V, Suttie J.W. Mechanism of action of vitamin K: evidence for the conversion of a precursor protein to prothrombin in the rat. Proc Natl Acad Sci 1971; 68: 1653-7.
    CrossrefPubMedGoogle Scholar
  • 76 Shearer M.J, Allan V.E, Haroon Y, Barkhan P. Nutritional aspects of vitamin K in the human. In: Suttie J.W. Vitamin K Metabolism and Vitamin K-Dependent Proteins. Baltimore: University Park Press; 1979: 317-27.
    Google Scholar
  • 77 Shearer M.J, BcBurney A, Barkhan P. Studies over the absorption and metabolism of phylloqui-none (Vitamin K1) in man. Vitam Horm 1974; 32: 513-42.
    PubMedGoogle Scholar
  • 78 Shearer M.J, Crampton O.E, McCarthy P.T, Mattock M.B. Vitamin K in plasma: measurement and relationship to vitamin K status, age, pregnancy, diet and disease. In: Sutor A.H, Künzer W. (eds) Physiologie und Pathophysiologie des Vitamin K. Basel/Grenzach-Wyhlen: Editiones Roche; 1986: 95-104.
    Google Scholar
  • 79 Shearer M.J, Rahim S, Barkhan P, Stimmler L. Plasma vitamin K1 in mothers and their newborn babies. Lancet 1982; II: 460-3.
    PubMedGoogle Scholar
  • 80 Smith C.R, Lipsky J.J. Hypoprothrombinemia and platelet dysfunction caused by cephalosporin and moxalactam antibiotics. J Antimicrob Chemother 1983; 11: 496-9.
    CrossrefPubMedGoogle Scholar
  • 81 Smith G, Sundboom J. The effects of 1-methyl-5-thiotetrazole in a rat liver vitamin K-dependent carboxylase assay. Thromb Res 1984; 33: 633-44.
    CrossrefPubMedGoogle Scholar
  • 82 Stenflo J. Structure and function of protein C. Semin Thromb Haemost 1984; 10: 109-21.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 Sunakawa K, Akita H, Iwata S, Sato Y. The influence of cefotaxime on intestinal flora and bleeding diathesis in infants and neonates, compared with other β-lactams. J Antimicrob Chemother 1984; 14(Suppl B): 317-24.
    CrossrefPubMedGoogle Scholar
  • 84 Suttie J.W. The fat-soluble vitamins. In: DeLuca H.F. Handbook of Lipid Research, Vol. 2. New York, London: Plenum Press; 1978: 211-77.
    Google Scholar
  • 85 Suttie J.W. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science 1973; 179: 192-4.
    CrossrefPubMedGoogle Scholar
  • 86 Suttie J.W. Mechanism of action of vitamin K: Synthesis of γ-carboxyglutamic acid. CRC Crit Rev Biochem 1980; 8: 191-223.
    PubMedGoogle Scholar
  • 87 Suttie J.W, Jackson C.M. Prothrombin structure, activation and biosynthesis. Physiol Rev 1977; 57: 1-70.
    CrossrefPubMedGoogle Scholar
  • 88 Uchida K, Ishigami T, Komeno T. Effects of latamoxef and methyltetrazolethiol on gamma-glutamylcarboxylase activity. Jpn J Pharmacol 1984; 35: 330-3.
    CrossrefPubMedGoogle Scholar
  • 89 Uchida K, Ishigami T, Matsubara T, Narisada M. Effects of N-methyltetrazolethiol (NMTT) and NMTT containing antibiotics on γ-glutamylcarbo-xylation. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington 1984 (abstr).
    PubMedGoogle Scholar
  • 90 Uchida K, Komeno T. Relationship between dietary and intestinal vitamin K’s, clotting factor levels, plasma vitamin K and urinary Gla. Proceedings of the 17th Steenbock Symposium “Current Advances in Vitamin K Research”. University of Wisconsin-Madison. June 21-25, Madison (USA) 1987 (in press).
    PubMedGoogle Scholar
  • 91 Uchida K, Nomura Y, Takase T, Harauchi T, Yoshizaki T, Nakao H. Effects of fasting and vitamin K deficient diets on blood coagulation factors on conventional and germ-free rats. Thromb Res 1985; 39: 741-50.
    CrossrefPubMedGoogle Scholar
  • 92 Udall J.A. Human sources and absorption of vitamin K in relation to anticoagulant stability. JAMA 1965; 194: 107-9.
    PubMedGoogle Scholar
  • 93 Uotila L, Suttie J.W. Recent findings in understanding the biological function of vitamin K. Med Biol 1982; 60: 16-24.
    PubMedGoogle Scholar
  • 94 Uotila L, Suttie J.W. Inhibition of vitamin K-dependent carboxylase in vitro by cefamandole and its structural analogs. J Infect Dis 1983; 148: 571-8.
    CrossrefPubMedGoogle Scholar
  • 95 Wallin R, Martin F. Vitamin K-dependent carbo-xylation and vitamin K metabolism in liver - effects of warfarin. J Clin Invest 1985; 76: 1879-84.
    CrossrefPubMedGoogle Scholar
  • 96 Wessler S, Gitel S.N. Warfarin - from bedside to bench. N Engl J Med 1984; 311: 645-52.
    CrossrefPubMedGoogle Scholar
  • 97 Whitlon D.S, Sadowski J.A, Suttie J.W. Mechanism of cumariri action : significance of vitamin K epoxide reductase inhibition. Biochem 1978; 17: 1371-7.
    CrossrefPubMedGoogle Scholar
  • 98 Willingham A.K, Matschiner J.T. Changes in phylloquinone epoxide activity related to prothrombin synthesis and microsomal clotting activity in the rat. Biochem J 1974; 140: 435-41.
    CrossrefPubMedGoogle Scholar
  • 99 Wise R, Dent J. Stability of β-lactam antibiotics containing N-methylthiotetrazole side-chain. Lancet 1983; II: 624-5.
    PubMedGoogle Scholar
  • 100 Zaugg H. Sind salicylartige Analgetika Vitamin-K-Antagonisten?. Eine Deutung der spontanen subnormalen Quickwerte. Schweiz Med Wschr 1978; 108: 1277-8.
    PubMedGoogle Scholar
  • 101 Zbinden G, Schärer K, Studer A. Experimentelle Untersuchungen über Erythrozytenschädigung durch Menadionderivate im Vergleich zu Vitamin K1 . Schweiz Med Wschr 1957; 87: 1238.
    PubMedGoogle Scholar